menu
    • menu
    [{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Evive Biotech","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurobindo Pharma Limited \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo Pharma Limited \/ Evive Biotech"}]

    Find Hematology Drugs in Phase III Clinical Development in INDIA

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aurobindo Pharma Limited

                            India arrow
                            APGA Annual Conference
                            Not Confirmed

                            Aurobindo Pharma Limited

                            India arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benegrastim

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Evive Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aurobindo Unit, Evive Biotech Ink Licensing Pact to Commercialise CIN Treatment Product in US

                            Details : Under the terms of the agreement, Evive will be responsible for the ongoing development, manufacturing, registration, and supply of Ryzneuta (benegrastim), while Acrotech will use its sales and commercialisation capabilities to market and distribute the ...

                            Product Name : Ryzneuta

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            November 23, 2022

                            Lead Product(s) : Benegrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Evive Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zydus Lifesciences

                            India arrow
                            APGA Annual Conference
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desidustat

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : China Medical System Holdings Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Zydus inks pact with China Medical System to market Desidustat in Greater China

                            Details : Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.

                            Product Name : Oxemia

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 20, 2020

                            Lead Product(s) : Desidustat

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : China Medical System Holdings Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth